Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation

The metabolism of the fifth component of complement (C5), and its relatonship to metabolism of the third component of complement (C3), has been studied in normal subjects and patients by simultaneous administration of radioiodine labeled C5 and C3. In seven normal subjects the fractional catabolic r...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 59; no. 4; pp. 704 - 715
Main Authors Sissons, J G, Liebowitch, J, Amos, N, Peters, D K
Format Journal Article
LanguageEnglish
Published United States 01.04.1977
Subjects
Online AccessGet full text
ISSN0021-9738
DOI10.1172/JCI108689

Cover

Loading…
Abstract The metabolism of the fifth component of complement (C5), and its relatonship to metabolism of the third component of complement (C3), has been studied in normal subjects and patients by simultaneous administration of radioiodine labeled C5 and C3. In seven normal subjects the fractional catabolic rate of C5 ranged from 1.5 to 2.1% of the plasma pool/h and extravascular/intravascular distribution ratio from 0.22 to 0.78, these values being similar to those obtained for C3, and synthesis rate from 71 to 134 mug/kg per h, In patients with complement activation the increase in fractional catabolic rate of C5 was nearly always less than that of C3. The data also showed that there was increased extravascular distribution of C3 and C5 in most patients and considerable extravascular catabolism of both proteins in some. However, there were differences in metabolic parameters between patients with different types of complement activation. In patients with systemic lupus erythematosus, fractional catabolism and extravascular distribution of C3 and C5 were both increased, and there was marked extravascular catabolism of both proteins. There was increased fractional catabolism and extravascular distribution of C3 in patients with mesangiocapillary nephritis and (or) partial lipodystrophy, and fractional catabolism of C5 was also increased in three of six studies although distribution of C5 was always within the normal range; however, in two patients with nephritic factor in their serum fractional catabolism of C5 was normal despite markedly increased C3 turnover, suggesting that in patients with alternative pathway activation by nephritic factor little or no C5 convertase is generated.
AbstractList The metabolism of the fifth component of complement (C5), and its relatonship to metabolism of the third component of complement (C3), has been studied in normal subjects and patients by simultaneous administration of radioiodine labeled C5 and C3. In seven normal subjects the fractional catabolic rate of C5 ranged from 1.5 to 2.1% of the plasma pool/h and extravascular/intravascular distribution ratio from 0.22 to 0.78, these values being similar to those obtained for C3, and synthesis rate from 71 to 134 mug/kg per h, In patients with complement activation the increase in fractional catabolic rate of C5 was nearly always less than that of C3. The data also showed that there was increased extravascular distribution of C3 and C5 in most patients and considerable extravascular catabolism of both proteins in some. However, there were differences in metabolic parameters between patients with different types of complement activation. In patients with systemic lupus erythematosus, fractional catabolism and extravascular distribution of C3 and C5 were both increased, and there was marked extravascular catabolism of both proteins. There was increased fractional catabolism and extravascular distribution of C3 in patients with mesangiocapillary nephritis and (or) partial lipodystrophy, and fractional catabolism of C5 was also increased in three of six studies although distribution of C5 was always within the normal range; however, in two patients with nephritic factor in their serum fractional catabolism of C5 was normal despite markedly increased C3 turnover, suggesting that in patients with alternative pathway activation by nephritic factor little or no C5 convertase is generated.The metabolism of the fifth component of complement (C5), and its relatonship to metabolism of the third component of complement (C3), has been studied in normal subjects and patients by simultaneous administration of radioiodine labeled C5 and C3. In seven normal subjects the fractional catabolic rate of C5 ranged from 1.5 to 2.1% of the plasma pool/h and extravascular/intravascular distribution ratio from 0.22 to 0.78, these values being similar to those obtained for C3, and synthesis rate from 71 to 134 mug/kg per h, In patients with complement activation the increase in fractional catabolic rate of C5 was nearly always less than that of C3. The data also showed that there was increased extravascular distribution of C3 and C5 in most patients and considerable extravascular catabolism of both proteins in some. However, there were differences in metabolic parameters between patients with different types of complement activation. In patients with systemic lupus erythematosus, fractional catabolism and extravascular distribution of C3 and C5 were both increased, and there was marked extravascular catabolism of both proteins. There was increased fractional catabolism and extravascular distribution of C3 in patients with mesangiocapillary nephritis and (or) partial lipodystrophy, and fractional catabolism of C5 was also increased in three of six studies although distribution of C5 was always within the normal range; however, in two patients with nephritic factor in their serum fractional catabolism of C5 was normal despite markedly increased C3 turnover, suggesting that in patients with alternative pathway activation by nephritic factor little or no C5 convertase is generated.
The metabolism of the fifth component of complement (C5), and its relatonship to metabolism of the third component of complement (C3), has been studied in normal subjects and patients by simultaneous administration of radioiodine labeled C5 and C3. In seven normal subjects the fractional catabolic rate of C5 ranged from 1.5 to 2.1% of the plasma pool/h and extravascular/intravascular distribution ratio from 0.22 to 0.78, these values being similar to those obtained for C3, and synthesis rate from 71 to 134 mug/kg per h, In patients with complement activation the increase in fractional catabolic rate of C5 was nearly always less than that of C3. The data also showed that there was increased extravascular distribution of C3 and C5 in most patients and considerable extravascular catabolism of both proteins in some. However, there were differences in metabolic parameters between patients with different types of complement activation. In patients with systemic lupus erythematosus, fractional catabolism and extravascular distribution of C3 and C5 were both increased, and there was marked extravascular catabolism of both proteins. There was increased fractional catabolism and extravascular distribution of C3 in patients with mesangiocapillary nephritis and (or) partial lipodystrophy, and fractional catabolism of C5 was also increased in three of six studies although distribution of C5 was always within the normal range; however, in two patients with nephritic factor in their serum fractional catabolism of C5 was normal despite markedly increased C3 turnover, suggesting that in patients with alternative pathway activation by nephritic factor little or no C5 convertase is generated.
Author Liebowitch, J
Amos, N
Sissons, J G
Peters, D K
Author_xml – sequence: 1
  givenname: J G
  surname: Sissons
  fullname: Sissons, J G
– sequence: 2
  givenname: J
  surname: Liebowitch
  fullname: Liebowitch, J
– sequence: 3
  givenname: N
  surname: Amos
  fullname: Amos, N
– sequence: 4
  givenname: D K
  surname: Peters
  fullname: Peters, D K
BackLink https://www.ncbi.nlm.nih.gov/pubmed/845257$$D View this record in MEDLINE/PubMed
BookMark eNptUblOAzEQdRGOJFDQU7hCQiJg79qxt6BAEUdQEA3UltcHMdpdh7UD4if4ZpxD4azsmXeNZnqg0_jGAHCA0SnGLDu7HY0x4kNedEAXoQwPCpbzXdAL4RkhTAglO2CbE5pR1gUfdybK0lcu1NBbGKcGWmfjFCpfz5JvExftRVGZOlUnUDYauhhgayoZnW9g9LD-YxKnrtVfJifQNXCW-Okf4JtbB6w8oVTRvS7N9sCWlVUw--u3Dx6vLh9GN4PJ_fV4dDEZqIznxYAbTaiyBTN5aSyRjBY5oUgqgoasVIZqQ0tkMeZaoazUWtuSMG21lBzjnOd9cL7ync3L2miVpmhlJWatq2X7Lrx04ifSuKl48q8iZ1nGaNIfrfWtf5mbEEXtgjJVJRvj50HwnBOMWJaIh9-DNgmr_Sf4eAWr1ofQGrshYCQW1xSbaybu2S-ucnG5tTShq_5RfAJMvaiP
CitedBy_id crossref_primary_10_1371_journal_pone_0195909
crossref_primary_10_1016_0090_1229_89_90139_6
crossref_primary_10_3390_ijms252111679
crossref_primary_10_1074_jbc_M609858200
crossref_primary_10_1016_j_ymthe_2024_02_001
crossref_primary_10_1016_S0307_742X_21_00250_2
crossref_primary_10_1111_j_1445_5994_1989_tb00218_x
crossref_primary_10_1002_art_1780291207
crossref_primary_10_1038_nrd4657
crossref_primary_10_1016_S0140_6736_83_90464_6
crossref_primary_10_1007_BF00286138
crossref_primary_10_1111_j_1600_6143_2012_04124_x
crossref_primary_10_1182_bloodadvances_2016002832
crossref_primary_10_1016_S0272_6386_12_81018_3
crossref_primary_10_1007_BF00856851
crossref_primary_10_1038_s41598_017_01087_7
crossref_primary_10_1016_S0005_2736_02_00686_7
crossref_primary_10_1371_journal_pone_0187373
crossref_primary_10_1007_BF02431730
crossref_primary_10_1007_BF00292537
crossref_primary_10_1111_imr_13156
crossref_primary_10_2174_0929867326666191016115853
crossref_primary_10_1208_s12248_020_00539_9
crossref_primary_10_1021_acs_bioconjchem_6b00369
crossref_primary_10_1016_0090_1229_90_90144_F
crossref_primary_10_1016_S0272_6386_87_80088_4
crossref_primary_10_1038_ki_1984_113
crossref_primary_10_1007_BF00541371
crossref_primary_10_1097_AOG_0000000000002980
crossref_primary_10_1098_rsos_221597
crossref_primary_10_1016_j_dmpk_2018_10_003
crossref_primary_10_1038_ki_1979_51
crossref_primary_10_1016_0090_1229_89_90141_4
crossref_primary_10_1016_S0021_9258_18_55131_0
crossref_primary_10_1038_ki_1988_214
crossref_primary_10_1007_BF00878356
crossref_primary_10_1007_s00281_017_0661_x
crossref_primary_10_1111_imr_13165
crossref_primary_10_1016_S0272_6386_12_81068_7
crossref_primary_10_1111_imr_12392
ContentType Journal Article
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1172/JCI108689
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EndPage 715
ExternalDocumentID PMC372275
845257
10_1172_JCI108689
Genre Journal Article
Comparative Study
GroupedDBID ---
-~X
.55
.GJ
29K
2WC
3O-
53G
5GY
5RE
8F7
AAWTL
AAYXX
ABOCM
ACGFO
ACIHN
ACNCT
ACPRK
ADBBV
AEAQA
AENEX
AFFNX
AHMBA
AI.
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
CS3
D-I
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FRP
GROUPED_DOAJ
GX1
HYE
H~9
IAO
IEA
IHR
INH
IOF
IPO
J5H
KQ8
L7B
M1P
MVM
OK1
OVT
P2P
P6G
RPM
TEORI
TR2
TVE
VH1
VVN
W2D
WH7
WOQ
WOW
X7M
YOC
ZGI
ZXP
ZY1
.XZ
08G
08P
354
36B
3V.
5RS
7RV
7X7
88A
88E
8AO
8FE
8FH
8FI
8FJ
8R4
8R5
AAKAS
AAYOK
ABPMR
ABUWG
ADZCM
AFCHL
AFKRA
ASPBG
AVWKF
AZFZN
BBNVY
BCR
BCU
BEC
BENPR
BHPHI
BKEYQ
BLC
BPHCQ
BVXVI
CCPQU
CGR
CUY
CVF
EBD
ECM
EIF
EMOBN
EX3
FEDTE
FYUFA
HCIFZ
HMCUK
HVGLF
IHW
INR
IOV
ISR
ITC
LK8
M0L
M5~
M7P
N4W
NAPCQ
NPM
OBH
OCB
ODZKP
OFXIZ
OGEVE
OHH
OHT
OVD
OVIDX
PKN
PQQKQ
PROAC
PSQYO
Q2X
S0X
SJFOW
SV3
UHU
UKHRP
XSB
YFH
YHG
YKV
~H1
7X8
5PM
ID FETCH-LOGICAL-c2839-8ed45cf97e3bef4a7593450ac4067bce5de5b0f118dc02bdddfb47dfdaa811383
ISSN 0021-9738
IngestDate Thu Aug 21 18:08:46 EDT 2025
Thu Jul 10 19:56:34 EDT 2025
Wed Feb 19 00:21:37 EST 2025
Thu Apr 24 23:11:23 EDT 2025
Tue Jul 01 01:42:47 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2839-8ed45cf97e3bef4a7593450ac4067bce5de5b0f118dc02bdddfb47dfdaa811383
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink http://www.jci.org/articles/view/108689/files/pdf
PMID 845257
PQID 83841072
PQPubID 23479
PageCount 12
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_372275
proquest_miscellaneous_83841072
pubmed_primary_845257
crossref_primary_10_1172_JCI108689
crossref_citationtrail_10_1172_JCI108689
ProviderPackageCode CITATION
AAYXX
PublicationCentury 1900
PublicationDate 19770401
PublicationDateYYYYMMDD 1977-04-01
PublicationDate_xml – month: 4
  year: 1977
  text: 19770401
  day: 1
PublicationDecade 1970
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of clinical investigation
PublicationTitleAlternate J Clin Invest
PublicationYear 1977
References 820630 - Immunochemistry. 1976 Apr;13(4):317-24
62010 - J Exp Med. 1976 Oct 1;144(4):1062-75
978134 - J Exp Med. 1976 Oct 1;144(4):1076-93
939051 - Clin Exp Immunol. 1976 Jun;24(3):474-82
1067618 - Proc Natl Acad Sci U S A. 1976 Sep;73(9):3268-72
13484460 - Phys Med Biol. 1957 Jul;2(1):36-53
4219908 - Clin Exp Immunol. 1974 Nov;18(3):391-405
4817274 - Clin Sci Mol Med. 1974 Feb;46(2):223-9
1185108 - J Exp Med. 1975 Oct 1;142(4):856-63
6074005 - J Clin Invest. 1967 Dec;46(12):2021-34
4143312 - Lancet. 1974 Dec 7;2(7893):1350-2
809512 - J Immunol. 1975 Nov;115(5):1357-61
948757 - Science. 1976 Sep 10;193(4257):1011-3
1165475 - J Exp Med. 1975 Sep 1;142(3):760-72
1245733 - J Immunol. 1976 Jan;116(1):1-7
4468849 - Clin Exp Immunol. 1974 Mar;16(3):445-52
1246331 - N Engl J Med. 1976 Feb 26;294(9):461-5
62817 - J Exp Med. 1976 Nov 2;144(5):1147-63
1097571 - J Exp Med. 1975 Jul 1;142(1):139-50
4160044 - Int Arch Allergy Appl Immunol. 1966;29(2):185-9
4261220 - Immunochemistry. 1972 Jul;9(7):709-23
4627271 - N Engl J Med. 1972 Oct 26;287(17):835-40
4830223 - J Clin Invest. 1974 Jun;53(6):1578-87
5038771 - Clin Exp Immunol. 1972 May;11(1):21-9
950465 - J Immunol. 1976 Aug;117(2):630-4
14316946 - J Exp Med. 1965 Aug 1;122:277-98
1249423 - J Immunol. 1976 Feb;116(2):568-70
4573089 - Ciba Found Symp. 1972;9:113-30
4625395 - Clin Exp Immunol. 1972 Jul;11(3):311-20
1112981 - J Immunol. 1975 Feb;114(2 pt 2):815-22
References_xml – reference: 809512 - J Immunol. 1975 Nov;115(5):1357-61
– reference: 4219908 - Clin Exp Immunol. 1974 Nov;18(3):391-405
– reference: 948757 - Science. 1976 Sep 10;193(4257):1011-3
– reference: 1165475 - J Exp Med. 1975 Sep 1;142(3):760-72
– reference: 820630 - Immunochemistry. 1976 Apr;13(4):317-24
– reference: 978134 - J Exp Med. 1976 Oct 1;144(4):1076-93
– reference: 4160044 - Int Arch Allergy Appl Immunol. 1966;29(2):185-9
– reference: 4573089 - Ciba Found Symp. 1972;9:113-30
– reference: 950465 - J Immunol. 1976 Aug;117(2):630-4
– reference: 14316946 - J Exp Med. 1965 Aug 1;122:277-98
– reference: 1185108 - J Exp Med. 1975 Oct 1;142(4):856-63
– reference: 1097571 - J Exp Med. 1975 Jul 1;142(1):139-50
– reference: 1067618 - Proc Natl Acad Sci U S A. 1976 Sep;73(9):3268-72
– reference: 1112981 - J Immunol. 1975 Feb;114(2 pt 2):815-22
– reference: 1245733 - J Immunol. 1976 Jan;116(1):1-7
– reference: 6074005 - J Clin Invest. 1967 Dec;46(12):2021-34
– reference: 4261220 - Immunochemistry. 1972 Jul;9(7):709-23
– reference: 4627271 - N Engl J Med. 1972 Oct 26;287(17):835-40
– reference: 5038771 - Clin Exp Immunol. 1972 May;11(1):21-9
– reference: 1249423 - J Immunol. 1976 Feb;116(2):568-70
– reference: 4625395 - Clin Exp Immunol. 1972 Jul;11(3):311-20
– reference: 939051 - Clin Exp Immunol. 1976 Jun;24(3):474-82
– reference: 4143312 - Lancet. 1974 Dec 7;2(7893):1350-2
– reference: 1246331 - N Engl J Med. 1976 Feb 26;294(9):461-5
– reference: 4817274 - Clin Sci Mol Med. 1974 Feb;46(2):223-9
– reference: 62010 - J Exp Med. 1976 Oct 1;144(4):1062-75
– reference: 62817 - J Exp Med. 1976 Nov 2;144(5):1147-63
– reference: 13484460 - Phys Med Biol. 1957 Jul;2(1):36-53
– reference: 4468849 - Clin Exp Immunol. 1974 Mar;16(3):445-52
– reference: 4830223 - J Clin Invest. 1974 Jun;53(6):1578-87
SSID ssj0014454
Score 1.3095803
Snippet The metabolism of the fifth component of complement (C5), and its relatonship to metabolism of the third component of complement (C3), has been studied in...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 704
SubjectTerms Adolescent
Adult
Complement C3 - analysis
Complement C3 - metabolism
Complement C5 - analysis
Complement C5 - metabolism
Complement System Proteins - metabolism
Female
Hepatitis - metabolism
Humans
Kidney Failure, Chronic - metabolism
Lipodystrophy - metabolism
Lupus Erythematosus, Systemic - metabolism
Male
Middle Aged
Nephritis - metabolism
Title Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation
URI https://www.ncbi.nlm.nih.gov/pubmed/845257
https://www.proquest.com/docview/83841072
https://pubmed.ncbi.nlm.nih.gov/PMC372275
Volume 59
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECXcFCh6KbqkqLsSRQ89RK0kkqZ0DIIEqWG7h9qAb4IkkoiKWAoSOYd-RL-5Q5EU5TpAl4sgaBkJes_0kDPzBqEPTJSp5GEYSKLigLI0DXLGwZGTsWA85XnYlYvNF5PzFZ2u2Xo0uh1kLW3b4lP54866kv9BFY4BrrpK9h-Q7Y3CAdgHfGELCMP2rzCeyxYwvNR9LmyoX1WqSyXfXDW1jfJ3SeNmEdBmappYgUmC077nZs9Me1FdC29G3-g1WG9cvrqz2wly3HqIv3sGDvzdvgaz8tIePgfgGxCgMT791Pf7mlUwHMLTTL-qfkn7eGOSAxd-YG9dR2-7bitMZR_ng_wXV1gQBSk3Yi9ucLZy4dVw5aEbabnpWrz_D8C1ouz05ItuIWW6E-2qbC--Zmer2Sxbnq6X99D9GKYXkVvlsdEnSplV7zYvZBWpwPTn3vCuH7M3Ofk9x3bgtCwfo0f26-NjQ50naCTrp-jB3OZTPEM_PYNwozBAjzsG4R56fdgjfYSBPxj4gx1_cNvgzZ6Rjj_eyBGuauzYgzV7BjaxZ88hWp2dLk_OA9uhIyjBLU2DRArKSpVySQqpaM5ZSigL8xLcRF6UkgnJilDBJFaUYVwIIVRBuVAiz5MoIgl5jg5qeJEXCCes4HBjAaYUJROVTvJQh6CpJKRIIzVGH933zkorX6-7qFxm3TSWx1kPzRi97y-9Mpotd130zoGWwYiqw2R5LZvtTZaQhEYhj8fo0EDYG0l0EgAfo8kOtP1prdS-e6auLjrFdsLjmLOXf3zkK_TQ_zJeo4P2eivfgNPbFm87hv4CEeW3ow
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Metabolism+of+the+fifth+component+of+complement%2C+and+its+relation+to+metabolism+of+the+third+component%2C+in+patients+with+complement+activation&rft.jtitle=The+Journal+of+clinical+investigation&rft.au=Sissons%2C+J+G&rft.au=Liebowitch%2C+J&rft.au=Amos%2C+N&rft.au=Peters%2C+D+K&rft.date=1977-04-01&rft.issn=0021-9738&rft.volume=59&rft.issue=4&rft.spage=704&rft_id=info:doi/10.1172%2FJCI108689&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9738&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9738&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9738&client=summon